Published in:
01-12-2018 | ASO Author Reflections
ASO Author Reflections: Changes in Use of Neoadjuvant Chemotherapy Over Time—Highest Rates of Use Now in Triple-Negative and HER2+ Disease
Authors:
Brittany L. Murphy, MD MS, Judy C. Boughey, MD
Published in:
Annals of Surgical Oncology
|
Special Issue 3/2018
Login to get access
Excerpt
Initially, neoadjuvant chemotherapy (NAC) was predominantly used in locally advanced disease.
1,
2 However, NAC is now considered for any patient who would be recommended adjuvant chemotherapy based on clinical and histological examination at diagnosis.
2 NAC may downstage disease in both the breast and axilla, as well as allow the assessment of in vivo response to therapy.
1,
2 While tumor size and nodal involvement were the dominant factors in considering NAC initially, currently tumor biology is a key factor. Response rates to NAC are highest in HER2
+ disease and in triple-negative breast cancer.
3 Additionally, neoadjuvant endocrine therapy is increasingly considered for hormone receptor-positive disease. Our hypothesis was that use of NAC had changed over time with higher use in triple-negative and HER2+ disease than in hormone receptor (HR)+/HER2− disease. …